Type to search

Bioscience and pharmaceutical Insider Only News Public Companies

Prelude names president as it preps candidates

Avatar photo

WILMINGTON – Prelude Therapeutics, the burgeoning cancer treatment research company, recently named its first president while it furthers research on two lead drugs and preps two additional ones for studies. Dr. Jane Huang, the current chief medical officer for hematology at BeiGene, a global biotechnology company developing oral small molecules and monoclonal antibodies for cancer,

Want to Read More?

Paid DBT subscribers get unlimited access to all Insider content and much more. Learn more in our Insider FAQ.

Become an Insider Now

Already an Insider? Log In.


You Might also Like

Leave a Comment

Your email address will not be published. Required fields are marked *

Premier Digital Partners

© 2023 Delaware Business Times